SEC Form 4 · accession 0001179110-16-020113
OSIRIS THERAPEUTICS, INC. · OSIR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lode Debrabandere
Officer — President & CEO
Period of report
Feb 22, 2016
Accepted (ET)
Feb 24, 2016 · 8:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001360886
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1 | $5.08 | Feb 22, 2016 | D | 6,250 | D | Mar 23, 2016 | Mar 23, 2022 | Common Stock | 6,250 | 403,750 | D |
| Incentive Stock Option (right to buy)F1 | $7.73 | Feb 22, 2016 | D | 7,500 | D | Feb 12, 2017 | Feb 12, 2023 | Common Stock | 7,500 | 396,250 | D |
| Non-Qualified Stock Option (right to buy)F2 | $14.93 | Feb 22, 2016 | D | 34,686 | D | Feb 6, 2017 | Feb 6, 2024 | Common Stock | 34,686 | 361,564 | D |
| Non-Qualified Stock Option (right to buy)F2 | $14.93 | Feb 22, 2016 | D | 30,803 | D | Feb 6, 2018 | Feb 6, 2024 | Common Stock | 30,803 | 330,761 | D |
| Incentive Stock Option (right to buy)F1 | $14.93 | Feb 22, 2016 | D | 2,814 | D | Feb 6, 2017 | Feb 6, 2024 | Common Stock | 2,814 | 327,947 | D |
| Incentive Stock Option (right to buy)F1 | $14.93 | Feb 22, 2016 | D | 6,697 | D | Feb 6, 2018 | Feb 6, 2024 | Common Stock | 6,697 | 321,250 | D |
| Non-Qualified Stock OptionsF2 | $18.40 | Feb 22, 2016 | D | 18,750 | D | Mar 6, 2016 | Mar 6, 2025 | Common Stock | 18,750 | 302,500 | D |
| Non-Qualified Stock OptionF2 | $18.40 | Feb 22, 2016 | D | 18,750 | D | Mar 6, 2017 | Mar 6, 2025 | Common Stock | 18,750 | 283,750 | D |
| Non-Qualified Stock Option (right to buy)F2 | $18.40 | Feb 22, 2016 | D | 18,750 | D | Mar 6, 2018 | Mar 6, 2025 | Common Stock | 18,750 | 265,000 | D |
| Non-Qualified Stock Option (right to buy)F2 | $18.40 | Feb 22, 2016 | D | 13,316 | D | Mar 6, 2019 | Mar 25, 2025 | Common Stock | 13,316 | 251,684 | D |
| Incentive Stock Option (right to buy)F1 | $18.40 | Feb 22, 2016 | D | 5,434 | D | Mar 6, 2019 | Mar 6, 2025 | Common Stock | 5,434 | 246,250 | D |
Explanation of responses
- F1Unvested incentive stock option that were forfeited concurrent with the Reporting Person's execution of post-resignation separation agreement, consistent with the provisions of the Amended and Restated 2006 Omnibus Plan. The Reporting Person's stock options that were vested on the date that he executed the separation agreement will remain exercisable for 90 days from the resignation date. The expiration of certain options were extended to one year as detailed in the separation agreement disclosed in the related Form 8-K.
- F2Unvested non-qualified stock option that were forfeited concurrent with the Reporting Person's execution of post-resignation separation agreement, consistent with the provisions of the Amended and Restated 2006 Omnibus Plan. The Reporting Person's stock options that were vested on the date that he executed the separation agreement will remain exercisable for 90 days from the resignation date. The expiration of certain options were extended to one year as detailed in the separation agreement disclosed in the related Form 8-K.